Adaptive Biotechnologies (ADPT) CCO Bobulsky sells 3,000 shares under plan

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp executive Susan Bobulsky, Chief Commercial Officer, MRD, reported selling 3,000 shares of common stock on August 10, 2026 at $25.00 per share in an open market or private transaction. Following this sale, she directly holds 396,989 shares. The transaction was effected under a Rule 10b5-1 trading plan adopted on December 16, 2025.

Insider Trade Summary 10b5-1

Net Seller: 3,000 shares

Net Sell 1 txn

Insider BOBULSKY SUSAN

Role Chief Commercial Officer, MRD

Sold 3,000 shs ($75K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	3,000	$25.00	$75K

Holdings After Transaction: Common Stock — 396,989 shares (Direct)

Footnotes (1)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.

Key Figures

Shares sold: 3,000 shares Sale price: $25.00 per share Shares held after sale: 396,989 shares +1 more

4 metrics

Shares sold 3,000 shares Common stock sale on August 10, 2026

Sale price $25.00 per share Price for the 3,000 shares of common stock sold

Shares held after sale 396,989 shares Direct holdings of Susan Bobulsky following the transaction

10b5-1 plan adoption date December 16, 2025 Adoption date of trading plan governing the reported sale

Key Terms

Rule 10b5-1 trading plan, open market or private transaction, Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported ... were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction financial

"Sale in open market or private transaction"

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 07:33 PM Accepted by SEC EDGAR 08/12/2026 - 07:33 PM Learn about SEC filing dates

FAQ

What insider transaction did ADPT executive Susan Bobulsky report?

Susan Bobulsky reported a sale of 3,000 shares of Adaptive Biotechnologies common stock on August 10, 2026 at $25.00 per share, executed as an open market or private transaction under a Rule 10b5-1 trading plan.

How many ADPT shares does Susan Bobulsky hold after the reported sale?

After the transaction, Susan Bobulsky directly holds 396,989 shares of Adaptive Biotechnologies common stock. This post-transaction holding is disclosed alongside the sale of 3,000 shares executed on August 10, 2026.

At what price did the ADPT insider shares sell in the recent transaction?

The reported sale was executed at $25.00 per share for 3,000 shares of Adaptive Biotechnologies common stock. The filing characterizes the transaction as a sale in an open market or private transaction.

Was the recent ADPT insider sale made under a Rule 10b5-1 plan?

Yes. The company reports that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Susan Bobulsky on December 16, 2025, indicating the sales were pre-arranged under that plan.

What role does the reporting person hold at Adaptive Biotechnologies (ADPT)?

The reporting person, Susan Bobulsky, serves as Chief Commercial Officer, MRD at Adaptive Biotechnologies. Her executive role is disclosed along with the reported sale of 3,000 shares of common stock.

How many ADPT shares were sold in total in this insider transaction?

The Form 4 reports a total sale of 3,000 shares of Adaptive Biotechnologies common stock. There were no reported purchases or derivative exercises in this filing, only this single sale transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOBULSKY SUSAN

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WASHINGTON 98109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer, MRD

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/10/2026		S(1)		3,000	D	$25	396,989	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.

	Susan Bobulsky by Kyle Piskel, Attorney-in-Fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)